Strategic Partnerships NorthStar has strategic collaborations with LIFT, QSA Global and Bioemtech to advance radiopharmaceutical development and supply, creating ready-made entry points for partners seeking contract development, manufacturing and long-term radiopharmaceutical supply.

Domestic Manufacturing A newly expanded Beloit manufacturing footprint enables scalable, onshore production of Cu-67 and Ac-225, strengthening NorthStar’s value proposition as a reliable domestic supplier for cancer radiopharmaceutical programs.

Ac-225 Leadership With plans to be among the first commercial producers of non-carrier-added Ac-225, NorthStar offers potential customers a secure alpha-therapy supply chain through long-term agreements and collaboration across preclinical to clinical stages.

CMDO Capabilities NorthStar’s CMDO/CMO unit provides customized radiopharmaceutical development and manufacturing services, presenting opportunities to fast-track partner programs from discovery to commercialization with regulatory support and scalable production.

Growth Signals Recent leadership hires and active participation in major healthcare events indicate a growth-oriented strategy and readiness to engage in strategic partnerships and co-development deals with biotech and pharma partners.